454 related articles for article (PubMed ID: 25367136)
1. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
Machova Polakova K; Kulvait V; Benesova A; Linhartova J; Klamova H; Jaruskova M; de Benedittis C; Haferlach T; Baccarani M; Martinelli G; Stopka T; Ernst T; Hochhaus A; Kohlmann A; Soverini S
J Cancer Res Clin Oncol; 2015 May; 141(5):887-99. PubMed ID: 25367136
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
[TBL] [Abstract][Full Text] [Related]
4. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
5. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
Shih LY; Kuo MC; Kuo CY; Lin TH; Bai LY; Chen TY; Wang MC; Lin TL; Lan YJ; Chen CC; Yang Y; Hsiao PC; Lai CL; Chang CH; Lin TH
Leuk Res; 2013 Jan; 37(1):43-9. PubMed ID: 23062378
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Khorashad JS; Kelley TW; Szankasi P; Mason CC; Soverini S; Adrian LT; Eide CA; Zabriskie MS; Lange T; Estrada JC; Pomicter AD; Eiring AM; Kraft IL; Anderson DJ; Gu Z; Alikian M; Reid AG; Foroni L; Marin D; Druker BJ; O'Hare T; Deininger MW
Blood; 2013 Jan; 121(3):489-98. PubMed ID: 23223358
[TBL] [Abstract][Full Text] [Related]
7. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
Parker WT; Lawrence RM; Ho M; Irwin DL; Scott HS; Hughes TP; Branford S
J Clin Oncol; 2011 Nov; 29(32):4250-9. PubMed ID: 21990409
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
9. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Jabbour E; Branford S; Saglio G; Jones D; Cortes JE; Kantarjian HM
Cancer; 2011 May; 117(9):1800-11. PubMed ID: 21509757
[TBL] [Abstract][Full Text] [Related]
10. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Soverini S; Bavaro L; De Benedittis C; Martelli M; Iurlo A; Orofino N; Sica S; Sorà F; Lunghi F; Ciceri F; Galimberti S; Baratè C; Bonifacio M; Scaffidi L; Castagnetti F; Gugliotta G; Albano F; Russo Rossi AV; Stagno F; di Raimondo F; D'Adda M; di Bona E; Abruzzese E; Binotto G; Sancetta R; Salvucci M; Capodanno I; Girasoli M; Coluzzi S; Attolico I; Musolino C; Calistri E; Annunziata M; Bocchia M; Stella S; Serra A; Errichiello S; Saglio G; Pane F; Vigneri P; Mignone F; Laginestra MA; Pileri SA; Percesepe A; Tenti E; Rosti G; Baccarani M; Cavo M; Martinelli G
Blood; 2020 Feb; 135(8):534-541. PubMed ID: 31877211
[TBL] [Abstract][Full Text] [Related]
11. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
[TBL] [Abstract][Full Text] [Related]
12. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Ernst T; Gruber FX; Pelz-Ackermann O; Maier J; Pfirrmann M; Müller MC; Mikkola I; Porkka K; Niederwieser D; Hochhaus A; Lange T
Haematologica; 2009 Sep; 94(9):1227-35. PubMed ID: 19608684
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
[TBL] [Abstract][Full Text] [Related]
14. Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia.
Strhakova L; Bujalkova MG; Hojsikova I; Lukackova R; Behulova R; Mistrik M; Repiska V
Neoplasma; 2011; 58(6):548-53. PubMed ID: 21895409
[TBL] [Abstract][Full Text] [Related]
15. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G
Oncologist; 2011; 16(6):868-76. PubMed ID: 21632458
[TBL] [Abstract][Full Text] [Related]
16. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
17. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Kwan TK; Ma ES; Chan YY; Wan TS; Liu HS; Sim JP; Yeung YM; Lie AK; Yip SF
Hong Kong Med J; 2009 Oct; 15(5):365-73. PubMed ID: 19801694
[TBL] [Abstract][Full Text] [Related]
19. Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.
Kim D; Kim DW; Cho BS; Goh HG; Kim SH; Kim WS; Lee J; Kweon IY; Park SH; Yoon JH; Kim ND; Chun H
Leuk Res; 2009 Sep; 33(9):1260-5. PubMed ID: 19201023
[TBL] [Abstract][Full Text] [Related]
20. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.
Soverini S; Abruzzese E; Bocchia M; Bonifacio M; Galimberti S; Gozzini A; Iurlo A; Luciano L; Pregno P; Rosti G; Saglio G; Stagno F; Tiribelli M; Vigneri P; Barosi G; Breccia M
J Hematol Oncol; 2019 Dec; 12(1):131. PubMed ID: 31801582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]